Novartis, makers of the kidney cancer drugs Everolimus, has proposed a lower price than the initial 2,822 a pack, equivalent to £34,235 a year, which they have not revealed but claim to be discussing with the Department of Health.

They stated that the drugs could double the average time without tumor growth in patients with worst advanced RCC and did not respond to treatment.

However, Britain's drug rationing body, National Institute for Health and Clinical Excellence, has expressed that it could not recommend the drugs as it does not provide enough benefits to justify its high cost, irrespective of the proposed discount.

Also, they said recommending the drugs to advanced kidney cancer patients will only give them an overall survival gain of more than three months.

The Head of Policy at Macmillan Cancer Support, Mike Hobday, has stated that the advanced kidney cancer patients will be disappointed as they have repeatedly lost out on getting drugs on the NHS.

Moreover, drugs for rarer cancers are often expensive as they are said to be harder to develop and are created for a smaller amount of people.

NICE has stated that the only hope of the patients is to turn to the Government’s new £200million a year Cancer Drugs Fund, which will fund treatments for wide-spread use.